Residual homing of α4β7-expressing β1+PI16+ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab.

Emily BeckerMark DeddenChristine GallMaximilian WiendlArif Bülent EkiciAnja Schulz-KuhntAnna SchwedaCaroline VoskensAhmed HegazyFrancesco VitaliRaja AtreyaTanja Martina MüllerImke AtreyaMarkus Friedrich Neurath Sebastian Zundler

Published in: Gut (2021)

Completely blocking TEff cell trafficking with vedolizumab, while simultaneously permitting residual homing of powerful TReg cells in an optimal 'therapeutic window' based on target exposure levels might be a strategy to optimise treatment outcomes in patients with IBD.

Keyphrases

regulatory t cells
ulcerative colitis
induced apoptosis
dendritic cells
patients with inflammatory bowel disease
single cell
cell cycle arrest
cell therapy
stem cells
endoplasmic reticulum stress
oxidative stress
signaling pathway
immune response
anti inflammatory
mesenchymal stem cells
pi k akt